OBJECTIVE: In the presurgical workup of magnetic resonance imaging (MRI)-negative (MRI(-) or "nonlesional") pharmacoresistant focal epilepsy (PFE) patients, discovering a previously undetected lesion can drastically change the evaluation and likely improve surgical outcome. Our study utilizes a voxel-based MRI postprocessing technique, implemented in a morphometric analysis program (MAP), to facilitate detection of subtle abnormalities in a consecutive cohort of MRI(-) surgical candidates. METHODS: Included in this retrospective study was a consecutive cohort of 150 MRI(-) surgical patients. MAP was performed on T1-weighted MRI, with comparison to a scanner-specific normal database. Review and analysis of MAP were performed blinded to patients' clinical information. The pertinence of MAP(+) areas was confirmed by surgical outcome and pathology. RESULTS: MAP showed a 43% positive rate, sensitivity of 0.9, and specificity of 0.67. Overall, patients with the MAP(+) region completely resected had the best seizure outcomes, followed by the MAP(-) patients, and patients who had no/partial resection of the MAP(+) region had the worst outcome (p < 0.001). Subgroup analysis revealed that visually identified subtle findings are more likely correct if also MAP(+) . False-positive rate in 52 normal controls was 2%. Surgical pathology of the resected MAP(+) areas contained mainly non-balloon-cell focal cortical dysplasia (FCD). Multiple MAP(+) regions were present in 7% of patients. INTERPRETATION: MAP can be a practical and valuable tool to: (1) guide the search for subtle MRI abnormalities and (2) confirm visually identified questionable abnormalities in patients with PFE due to suspected FCD. A MAP(+) region, when concordant with the patient's electroclinical presentation, should provide a legitimate target for surgical exploration.
OBJECTIVE: In the presurgical workup of magnetic resonance imaging (MRI)-negative (MRI(-) or "nonlesional") pharmacoresistant focal epilepsy (PFE) patients, discovering a previously undetected lesion can drastically change the evaluation and likely improve surgical outcome. Our study utilizes a voxel-based MRI postprocessing technique, implemented in a morphometric analysis program (MAP), to facilitate detection of subtle abnormalities in a consecutive cohort of MRI(-) surgical candidates. METHODS: Included in this retrospective study was a consecutive cohort of 150 MRI(-) surgical patients. MAP was performed on T1-weighted MRI, with comparison to a scanner-specific normal database. Review and analysis of MAP were performed blinded to patients' clinical information. The pertinence of MAP(+) areas was confirmed by surgical outcome and pathology. RESULTS: MAP showed a 43% positive rate, sensitivity of 0.9, and specificity of 0.67. Overall, patients with the MAP(+) region completely resected had the best seizure outcomes, followed by the MAP(-) patients, and patients who had no/partial resection of the MAP(+) region had the worst outcome (p < 0.001). Subgroup analysis revealed that visually identified subtle findings are more likely correct if also MAP(+) . False-positive rate in 52 normal controls was 2%. Surgical pathology of the resected MAP(+) areas contained mainly non-balloon-cell focal cortical dysplasia (FCD). Multiple MAP(+) regions were present in 7% of patients. INTERPRETATION: MAP can be a practical and valuable tool to: (1) guide the search for subtle MRI abnormalities and (2) confirm visually identified questionable abnormalities in patients with PFE due to suspected FCD. A MAP(+) region, when concordant with the patient's electroclinical presentation, should provide a legitimate target for surgical exploration.
Authors: Horst Urbach; Björn Scheffler; Thomas Heinrichsmeier; Joachim von Oertzen; Thomas Kral; Joerg Wellmer; Johannes Schramm; Otmar D Wiestler; Ingmar Blümcke Journal: Epilepsia Date: 2002-01 Impact factor: 5.864
Authors: Jason M Bruggemann; Marko Wilke; Seu S Som; Ann M E Bye; Andrew Bleasel; John A Lawson Journal: Epilepsy Res Date: 2007-11-09 Impact factor: 3.045
Authors: Samson B Antel; D Louis Collins; Neda Bernasconi; Frederick Andermann; Rajjan Shinghal; Robert E Kearney; Douglas L Arnold; Andrea Bernasconi Journal: Neuroimage Date: 2003-08 Impact factor: 6.556
Authors: Samson B Antel; Andrea Bernasconi; Neda Bernasconi; D Louis Collins; Robert E Kearney; Rajjan Shinghal; Douglas L Arnold Journal: Neuroimage Date: 2002-12 Impact factor: 6.556
Authors: Tuuli M Salmenpera; Mark R Symms; Fergus J Rugg-Gunn; Philip A Boulby; Samantha L Free; Gareth J Barker; Tarek A Yousry; John S Duncan Journal: Epilepsia Date: 2007-02 Impact factor: 5.864
Authors: Shahin Tavakol; Jessica Royer; Alexander J Lowe; Leonardo Bonilha; Joseph I Tracy; Graeme D Jackson; John S Duncan; Andrea Bernasconi; Neda Bernasconi; Boris C Bernhardt Journal: Epilepsia Date: 2019-03-19 Impact factor: 5.864
Authors: T Demerath; L Rubensdörfer; R Schwarzwald; A Schulze-Bonhage; D-M Altenmüller; C Kaller; T Kober; H-J Huppertz; H Urbach Journal: AJNR Am J Neuroradiol Date: 2020-06-04 Impact factor: 3.825
Authors: Yee-Leng Tan; Hosung Kim; Seunghyun Lee; Tarik Tihan; Lawrence Ver Hoef; Susanne G Mueller; Anthony James Barkovich; Duan Xu; Robert Knowlton Journal: Neuroimage Date: 2017-10-31 Impact factor: 6.556
Authors: Z Irene Wang; P Suwanpakdee; S E Jones; Z Jaisani; Ahsan N V Moosa; I M Najm; F von Podewils; R C Burgess; B Krishnan; R A Prayson; J A Gonzalez-Martinez; W Bingaman; A V Alexopoulos Journal: J Neurol Date: 2016-06-13 Impact factor: 4.849